Gene expression signature of atypical breast hyperplasia and regulation by SFRP1

Abstract Background Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at 4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen receptor alpha positive (ERα+) and represent risk indicators and/or precurso...

Full description

Bibliographic Details
Main Authors: Kelly J. Gregory, Amy L. Roberts, Erin M. Conlon, Jacob A. Mayfield, Mary J. Hagen, Giovanna M. Crisi, Brooke A. Bentley, Jeffrey J. Kane, Grace Makari-Judson, Holly S. Mason, Jun Yu, Lihua Julie Zhu, Karl Simin, Jacob P. S. Johnson, Ashraf Khan, Ben R. Schneider, Sallie S. Schneider, D. Joseph Jerry
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Breast Cancer Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13058-019-1157-5
id doaj-14367b64f7854897a6a4e3a757b9c8bf
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Kelly J. Gregory
Amy L. Roberts
Erin M. Conlon
Jacob A. Mayfield
Mary J. Hagen
Giovanna M. Crisi
Brooke A. Bentley
Jeffrey J. Kane
Grace Makari-Judson
Holly S. Mason
Jun Yu
Lihua Julie Zhu
Karl Simin
Jacob P. S. Johnson
Ashraf Khan
Ben R. Schneider
Sallie S. Schneider
D. Joseph Jerry
spellingShingle Kelly J. Gregory
Amy L. Roberts
Erin M. Conlon
Jacob A. Mayfield
Mary J. Hagen
Giovanna M. Crisi
Brooke A. Bentley
Jeffrey J. Kane
Grace Makari-Judson
Holly S. Mason
Jun Yu
Lihua Julie Zhu
Karl Simin
Jacob P. S. Johnson
Ashraf Khan
Ben R. Schneider
Sallie S. Schneider
D. Joseph Jerry
Gene expression signature of atypical breast hyperplasia and regulation by SFRP1
Breast Cancer Research
Atypical hyperplasia
Breast
Lobular
Ductal
Premalignancy
SFRP1
author_facet Kelly J. Gregory
Amy L. Roberts
Erin M. Conlon
Jacob A. Mayfield
Mary J. Hagen
Giovanna M. Crisi
Brooke A. Bentley
Jeffrey J. Kane
Grace Makari-Judson
Holly S. Mason
Jun Yu
Lihua Julie Zhu
Karl Simin
Jacob P. S. Johnson
Ashraf Khan
Ben R. Schneider
Sallie S. Schneider
D. Joseph Jerry
author_sort Kelly J. Gregory
title Gene expression signature of atypical breast hyperplasia and regulation by SFRP1
title_short Gene expression signature of atypical breast hyperplasia and regulation by SFRP1
title_full Gene expression signature of atypical breast hyperplasia and regulation by SFRP1
title_fullStr Gene expression signature of atypical breast hyperplasia and regulation by SFRP1
title_full_unstemmed Gene expression signature of atypical breast hyperplasia and regulation by SFRP1
title_sort gene expression signature of atypical breast hyperplasia and regulation by sfrp1
publisher BMC
series Breast Cancer Research
issn 1465-542X
publishDate 2019-06-01
description Abstract Background Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at 4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen receptor alpha positive (ERα+) and represent risk indicators and/or precursor lesions to low grade ERα+ tumors. Therefore, molecular profiles of AH lesions offer insights into the earliest changes in the breast epithelium, rendering it susceptible to oncogenic transformation. Methods In this study, women were selected who were diagnosed with ductal or lobular AH, but no breast cancer prior to or within the 2-year follow-up. Paired AH and histologically normal benign (HNB) tissues from patients were microdissected. RNA was isolated, amplified linearly, labeled, and hybridized to whole transcriptome microarrays to determine gene expression profiles. Genes that were differentially expressed between AH and HNB were identified using a paired analysis. Gene expression signatures distinguishing AH and HNB were defined using AGNES and PAM methods. Regulation of gene networks was investigated using breast epithelial cell lines, explant cultures of normal breast tissue and mouse tissues. Results A 99-gene signature discriminated the histologically normal and AH tissues in 81% of the cases. Network analysis identified coordinated alterations in signaling through ERα, epidermal growth factor receptors, and androgen receptor which were associated with the development of both lobular and ductal AH. Decreased expression of SFRP1 was also consistently lower in AH. Knockdown of SFRP1 in 76N-Tert cells resulted altered expression of 13 genes similarly to that observed in AH. An SFRP1-regulated network was also observed in tissues from mice lacking Sfrp1. Re-expression of SFRP1 in MCF7 cells provided further support for the SFRP1-regulated network. Treatment of breast explant cultures with rSFRP1 dampened estrogen-induced progesterone receptor levels. Conclusions The alterations in gene expression were observed in both ductal and lobular AH suggesting shared underlying mechanisms predisposing to AH. Loss of SFRP1 expression is a significant regulator of AH transcriptional profiles driving previously unidentified changes affecting responses to estrogen and possibly other pathways. The gene signature and pathways provide insights into alterations contributing to AH breast lesions.
topic Atypical hyperplasia
Breast
Lobular
Ductal
Premalignancy
SFRP1
url http://link.springer.com/article/10.1186/s13058-019-1157-5
work_keys_str_mv AT kellyjgregory geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT amylroberts geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT erinmconlon geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT jacobamayfield geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT maryjhagen geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT giovannamcrisi geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT brookeabentley geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT jeffreyjkane geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT gracemakarijudson geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT hollysmason geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT junyu geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT lihuajuliezhu geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT karlsimin geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT jacobpsjohnson geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT ashrafkhan geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT benrschneider geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT salliesschneider geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
AT djosephjerry geneexpressionsignatureofatypicalbreasthyperplasiaandregulationbysfrp1
_version_ 1721569433299714048
spelling doaj-14367b64f7854897a6a4e3a757b9c8bf2021-04-02T12:19:37ZengBMCBreast Cancer Research1465-542X2019-06-0121111810.1186/s13058-019-1157-5Gene expression signature of atypical breast hyperplasia and regulation by SFRP1Kelly J. Gregory0Amy L. Roberts1Erin M. Conlon2Jacob A. Mayfield3Mary J. Hagen4Giovanna M. Crisi5Brooke A. Bentley6Jeffrey J. Kane7Grace Makari-Judson8Holly S. Mason9Jun Yu10Lihua Julie Zhu11Karl Simin12Jacob P. S. Johnson13Ashraf Khan14Ben R. Schneider15Sallie S. Schneider16D. Joseph Jerry17Pioneer Valley Life Sciences InstituteDepartment of Veterinary and Animal Sciences, University of Massachusetts-AmherstDepartment of Mathematics and Statistics, University of MassachusettsDivision of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical SchoolDepartment of Veterinary and Animal Sciences, University of Massachusetts-AmherstDepartment of Pathology, University of Massachusetts Medical School/BaystateDepartment of Pathology, University of Massachusetts Medical School/BaystatePioneer Valley Life Sciences InstituteDivision of Hematology-Oncology, University of Massachusetts Medical School/BaystateDepartment of Surgery, University of Massachusetts Medical School/BaystateUniversity of Massachusetts Medical School, Molecular, Cell, and Cancer BiologyUniversity of Massachusetts Medical School, Molecular, Cell, and Cancer BiologyUniversity of Massachusetts Medical School, Molecular, Cell, and Cancer BiologyUniversity of Massachusetts Medical School, Molecular, Cell, and Cancer BiologyDepartment of Pathology, University of Massachusetts Medical SchoolPioneer Valley Life Sciences InstitutePioneer Valley Life Sciences InstitutePioneer Valley Life Sciences InstituteAbstract Background Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at 4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen receptor alpha positive (ERα+) and represent risk indicators and/or precursor lesions to low grade ERα+ tumors. Therefore, molecular profiles of AH lesions offer insights into the earliest changes in the breast epithelium, rendering it susceptible to oncogenic transformation. Methods In this study, women were selected who were diagnosed with ductal or lobular AH, but no breast cancer prior to or within the 2-year follow-up. Paired AH and histologically normal benign (HNB) tissues from patients were microdissected. RNA was isolated, amplified linearly, labeled, and hybridized to whole transcriptome microarrays to determine gene expression profiles. Genes that were differentially expressed between AH and HNB were identified using a paired analysis. Gene expression signatures distinguishing AH and HNB were defined using AGNES and PAM methods. Regulation of gene networks was investigated using breast epithelial cell lines, explant cultures of normal breast tissue and mouse tissues. Results A 99-gene signature discriminated the histologically normal and AH tissues in 81% of the cases. Network analysis identified coordinated alterations in signaling through ERα, epidermal growth factor receptors, and androgen receptor which were associated with the development of both lobular and ductal AH. Decreased expression of SFRP1 was also consistently lower in AH. Knockdown of SFRP1 in 76N-Tert cells resulted altered expression of 13 genes similarly to that observed in AH. An SFRP1-regulated network was also observed in tissues from mice lacking Sfrp1. Re-expression of SFRP1 in MCF7 cells provided further support for the SFRP1-regulated network. Treatment of breast explant cultures with rSFRP1 dampened estrogen-induced progesterone receptor levels. Conclusions The alterations in gene expression were observed in both ductal and lobular AH suggesting shared underlying mechanisms predisposing to AH. Loss of SFRP1 expression is a significant regulator of AH transcriptional profiles driving previously unidentified changes affecting responses to estrogen and possibly other pathways. The gene signature and pathways provide insights into alterations contributing to AH breast lesions.http://link.springer.com/article/10.1186/s13058-019-1157-5Atypical hyperplasiaBreastLobularDuctalPremalignancySFRP1